Pluristem Therapeutics (NASDAQ:PSTI)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Wednesday, AnalystRatings.com reports. They currently have a $15.50 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 379.88% from the company’s previous close.
Several other research firms also recently weighed in on PSTI. LADENBURG THALM/SH SH assumed coverage on shares of Pluristem Therapeutics in a research report on Monday, July 22nd. They issued a “buy” rating on the stock. ValuEngine downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $9.25.
Pluristem Therapeutics stock traded up $0.03 during mid-day trading on Wednesday, hitting $3.23. The company’s stock had a trading volume of 23,200 shares, compared to its average volume of 72,100. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.23 and a current ratio of 2.74. Pluristem Therapeutics has a 12 month low of $3.17 and a 12 month high of $11.90. The business has a 50 day moving average price of $3.55 and a 200-day moving average price of $2.47.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.